NVAX analyst estimates
Novavax (NVAX) analyst ratings, the average price target and its range, and every firm's latest call.
NVAX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 24, 2025 | Cantor Fitzgerald | Novavax initiated with an Overweight at Cantor Fitzgerald | $18.00 |
| Oct 23, 2025 | H.C. Wainwright | Novavax price target raised to $11 from $10 at H.C. Wainwright | $11.00 |
| Nov 18, 2024 | B.Riley Financial | Novavax (NVAX) PT Lowered to $22 at B.Riley | $22.00 |
| Oct 16, 2024 | Bank of America Securities | Novavax (NVAX) PT Lowered to $14 at BofA Securities 'to reflect delays in phase 3 CIC/standalone flu trial' | $14.00 |
| Oct 16, 2024 | Jefferies | Novavax (NVAX) PT Lowered to $25 at Jefferies | $25.00 |
| Jul 19, 2024 | Jefferies | Novavax price target lowered to $31 from $38 at Jefferies | $31.00 |
| May 10, 2024 | H.C. Wainwright | H.C. Wainwright reiterates Buy rating on Novavax after 'landmark' Sanofi deal | $19.00 |
| Feb 14, 2022 | Cantor Fitzgerald | Novavax (NVAX) Stock: $174 Price Target From Cantor Fitzgerald | $174.00 |
- 6 firms rate NVAX: 3 buy, 1 hold, 2 sell.
Updated 2026-11-03 00:05 UTC